July 18, 2012
/PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and only 16-contact percutaneous lead for spinal cord stimulation (SCS) therapy, and the Clik™ Anchor, an innovative locking system designed to secure and reduce unwanted migration of SCS leads. The research was presented at the International Spine Intervention Society (ISIS) 20th Annual Scientific Meeting in
Results from the Infinion 16 study demonstrated that this innovative lead, used in conjunction with the Precision™ Plus SCS System, delivered significant pain relief in patients with chronic pain. The Clik Anchor study, awarded Best Poster at the ISIS meeting, showed that this novel fixation device reduced lead migration, the most common complication associated with SCS therapy.
"Chronic pain affects the daily lives of more than 100 million Americans each year, and tens of thousands of patients with chronic pain have found that SCS systems help them manage their pain," said
, senior vice president and president of the Neuromodulation Division at Boston Scientific. "The Infinion 16 Lead and Clik Anchor studies underscore our commitment to developing industry-leading technologies that advance the management of chronic pain and mitigate difficulties associated with SCS therapy."
Initial Spinal Cord Stimulation Trial Outcomes with the Infinion 16 Lead
An analysis of 25 chronic pain patients who underwent an SCS trial showed that the Infinion 16 Lead delivered significant pain relief outcomes for those patients, including reduced pain intensity (p<0.0001) and improved pain relief (p<0.0001).
"The Infinion 16 is the only lead that provides 16 contacts that can be inserted through a single, small needle with just one lead placement," said
, M.D., pain management specialist at Vidant Roanoke-Chowan Hospital in
and lead author of the study. "Added coverage of the spinal cord provides me with more options to manage my patients' chronic pain."
Additionally, 88 percent of patients temporarily implanted with the Infinion 16 Lead met the criteria for permanent SCS implantation with the Precision Plus SCS System.